Peters, K.E.; Bringans, S.D.; O’Neill, R.S.; Lumbantobing, T.S.C.; Lui, J.K.C.; Davis, T.M.E.; Hansen, M.K.; Lipscombe, R.J.
Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. J. Clin. Med. 2023, 12, 3247.
https://doi.org/10.3390/jcm12093247
AMA Style
Peters KE, Bringans SD, O’Neill RS, Lumbantobing TSC, Lui JKC, Davis TME, Hansen MK, Lipscombe RJ.
Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. Journal of Clinical Medicine. 2023; 12(9):3247.
https://doi.org/10.3390/jcm12093247
Chicago/Turabian Style
Peters, Kirsten E., Scott D. Bringans, Ronan S. O’Neill, Tasha S. C. Lumbantobing, James K. C. Lui, Timothy M. E. Davis, Michael K. Hansen, and Richard J. Lipscombe.
2023. "Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores" Journal of Clinical Medicine 12, no. 9: 3247.
https://doi.org/10.3390/jcm12093247
APA Style
Peters, K. E., Bringans, S. D., O’Neill, R. S., Lumbantobing, T. S. C., Lui, J. K. C., Davis, T. M. E., Hansen, M. K., & Lipscombe, R. J.
(2023). Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. Journal of Clinical Medicine, 12(9), 3247.
https://doi.org/10.3390/jcm12093247
